KeyBanc analyst Matthew Gillmor lowered the firm’s price target on Tenet Healthcare (THC) to $185 from $200 and keeps an Overweight rating on the shares. The firm says that its revised price target reflects elevated policy uncertainty under the incoming Trump administration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target lowered to $175 from $190 at Truist
- Tenet Healthcare assumed with an Overweight at JPMorgan
- Netflix, MongoDB downgraded: Wall Street’s top analyst calls
- Tenet Healthcare downgraded to Neutral from Buy at Goldman Sachs
- Block, Five Below downgraded: Wall Street’s top analyst calls